ArticleAmerican journal of hypertension2013
Antihypertensive actions of moderate hyperbilirubinemia: role of superoxide inhibition.
Article in American journal of hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: A biomarker for insulin resistance in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome.Metabolism: clinical and experimental · 2025Review
- Bile Acids and Bilirubin Role in Oxidative Stress and Inflammation in Cardiovascular Diseases.Diseases (Basel, Switzerland) · 2024Review
- The physiology of bilirubin: health and disease equilibrium.Trends in molecular medicine · 2023Review
- Article
- Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease.Biomedicines · 2022Review
- Relationship Between Serum Indirect Bilirubin Levels and Cardiovascular Events and All-Cause Mortality in Maintenance Hemodialysis Patients.Therapeutics and clinical risk management · 2022Article
- Bilirubin as a metabolic hormone: the physiological relevance of low levels.American journal of physiology. Endocrinology and metabolism · 2021Review
- Life-Long Hyperbilirubinemia Exposure and Bilirubin Priming PreventFrontiers in pharmacology · 2021Article
- Serum bilirubin and ischaemic stroke: a review of literature.Stroke and vascular neurology · 2020Review
- Heme Oxygenase Dependent Bilirubin Generation in Vascular Cells: A Role in Preventing Endothelial Dysfunction in Local Tissue Microenvironment?Frontiers in physiology · 2020Review
- Non-urate transporter 1, non-glucose transporter member 9-related renal hypouricemia and acute renal failure accompanied by hyperbilirubinemia after anaerobic exercise: a case report.BMC nephrology · 2019Article
- Bilirubin Links Heme Metabolism to Neuroprotection by Scavenging Superoxide.Cell chemical biology · 2019Article
- Bilirubin, a Cardiometabolic Signaling Molecule.Hypertension (Dallas, Tex. : 1979) · 2018Review
- Bilirubin, a new therapeutic for kidney transplant?Transplantation reviews (Orlando, Fla.) · 2018Review
- Hyperbilirubinemia, Hypertension, and CKD: the Links.Current hypertension reports · 2017Review
- Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?Medical hypotheses · 2016Article
- Hyperbilirubinemia Protects against Aging-Associated Inflammation and Metabolic Deterioration.Oxidative medicine and cellular longevity · 2016Article
- Hyperbilirubinemia exaggerates endotoxin-induced hypothermia.Cell cycle (Georgetown, Tex.) · 2015Article
- Heme oxygenase induction attenuates TNF-α-induced hypertension in pregnant rodents.Frontiers in pharmacology · 2015Article
- Association between serum bilirubin and estimated glomerular filtration rate among elderly persons.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundModerate (approximately 2-fold) increases in plasma unconjugated bilirubin levels are able to attenuate the development of angiotensin II (Ang II)-dependent hypertension. To determine the specific role of decreases in superoxide production to the blood pressure-lowering effects of moderate hyperbilirubinemia (MHyB), we performed this study, in which the Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor apocynin was given to Ang II-infused mice in the presence and absence of moderate hyperbilirubinemia.
methodsApocynin (14mM) was administered in the drinking water prior to treatment with UDP-glucuronosyltransferase 1A1 antisense morpholino (16 μg/kg), which was administered by intravenous injection every third day. Treatments were started before the implantation of Ang II-containing minipumps (1μg/kg/min) and continued throughout the protocol.
resultsAng II infusion increased blood pressure to 145±2mm Hg. Apocynin treatment alone reduced blood pressure to 135±5mm Hg, whereas MHyB alone decreased blood pressure to 118±5mm Hg in Ang II-infused mice. Prior inhibition of NADPH oxidase with apocynin did not result in a further decrease in blood pressure in MHyB mice, which averaged 117±3mm Hg (n = 6 mice per group). In aortic preparations, apocynin treatment decreased Ang II-mediated superoxide production from 2433±120 relative light units (RLU)/min/mg to 1851±126 RLU/min/mg (n = 4 mice per group), which was similar to levels observed in MHyB mice alone (1473±132 RLU/min/mg) or in combination with apocynin (1503±115 RLU/min/mg).
conclusionsOur results indicate that MHyB lowers blood pressure by a mechanism that is partially dependent on the inhibition of superoxide production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.